| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Nuclear receptor coactivator 7, 140 kDa estrogen receptor-associated protein, Estrogen nuclear receptor coactivator 1, NCOA7, ERAP140, ESNA1 |
| Entrez GeneID | 135112 |
| WB Predicted band size | 106.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This NCOA7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 76-103 amino acids from the N-terminal region of human NCOA7. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于NCOA7(N-term)抗体的3篇参考文献，涵盖其功能研究和应用场景：
---
1. **文献名称**：*NCOA7 Links Antioxidant Defense and DNA Damage Response in Epithelial Cells*
**作者**：Smith J, et al.
**摘要**：本研究揭示了NCOA7在抗氧化应激中的关键作用，通过N端抗体(N-term)进行Western blot和免疫荧光分析，发现NCOA7与KEAP1/NRF2通路相互作用，增强细胞对氧化损伤的抵抗能力，并参与DNA修复机制。
2. **文献名称**：*NCOA7 as a Novel Coactivator in Estrogen Receptor-Positive Breast Cancer*
**作者**：Lee S, et al.
**摘要**：研究利用NCOA7(N-term)抗体进行免疫组化(IHC)和ChIP-seq分析，证明NCOA7通过N端结构域与雌激素受体(ERα)结合，促进乳腺癌细胞增殖及他莫昔芬耐药性，提示其作为潜在治疗靶点。
3. **文献名称**：*Proteomic Analysis of NCOA7 Interaction Network in Pancreatic Cancer*
**作者**：Zhang H, et al.
**摘要**：通过免疫共沉淀(Co-IP)结合质谱技术，使用NCOA7 N端抗体鉴定了其在胰腺癌细胞中的互作蛋白群，发现NCOA7通过调控mTOR信号通路影响肿瘤代谢和侵袭转移。
---
**备注**：上述文献为示例，实际研究中建议通过PubMed或Web of Science以“NCOA7 antibody N-terminal”为关键词检索最新文章，并关注抗体货号(如Abcam#12345)对应的引用文献以确保准确性。
The NCOA7 (N-term) antibody is a research tool designed to target the N-terminal region of Nuclear Receptor Coactivator 7 (NCOA7), a protein involved in transcriptional regulation and cellular signaling. NCOA7. also known as ERAP140 or HCOA7. belongs to the nuclear receptor coactivator family and interacts with hormone receptors like estrogen receptor alpha (ERα) and peroxisome proliferator-activated receptor gamma (PPARγ). Its N-terminal domain contains activation motifs critical for recruiting transcriptional machinery and mediating ligand-dependent gene expression.
This antibody is commonly used in techniques such as Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to detect endogenous NCOA7 protein levels, localization, or interaction partners. Studies employing this antibody have highlighted NCOA7's role in diverse processes, including oxidative stress response, lipid metabolism, and cancer progression. For example, it has been implicated in breast cancer pathogenesis through ERα signaling modulation and in metabolic disorders via PPARγ-regulated pathways.
The NCOA7 (N-term) antibody aids in elucidating the protein's regulatory mechanisms, post-translational modifications, and tissue-specific expression patterns. Validation typically includes testing on knockout cell lines or tissues to confirm specificity. Its applications extend to both basic research and translational studies exploring NCOA7's potential as a therapeutic target or biomarker in diseases like diabetes, cancer, and inflammation.
×
